$0.4116
0.02987.81%
Last update: Nov 11, 4:16 PM
Oncolytics Biotech Inc
ONCYNASDAQ
Oncolytics Biotech fell 64.6% from $1.08 to $0.38, behind the S&P 500's +9.8%. Its worst day was Oct 12 (−15.0%), and its low came Nov 10 at $0.38.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.10 missed the $-0.06 estimate on $0.00 revenue.
−4.8% · S&P 500 −1.7%
Oncolytics Biotech closed at its highest level of the year, 17.6% above where the year started.
Story events cover the past 12 months · Times ET
+8.5% · S&P 500 +0.5%
Oncolytics Biotech shares rose 27.0%, while the S&P 500 rose 0.1%.
+27.0%, the year's best day · S&P 500 +0.1%
EPS of $-0.09 missed the $-0.07 estimate on $0.00 revenue.
−4.2% · S&P 500 −0.3%
Oncolytics Biotech shares rose 14.8%, while the S&P 500 rose 0.6%.
+14.8% · S&P 500 +0.6%
EPS of $-0.06 beat the $-0.07 estimate on $0.00 revenue.
−2.6% · S&P 500 −1.2%
Oncolytics Biotech shares rose 16.1%, while the S&P 500 rose 0.8%.
+16.1% · S&P 500 +0.8%
EPS of $-0.08 missed the $-0.07 estimate on $0.00 revenue.
+0.5% · S&P 500 +0.3%
Oncolytics Biotech shares fell 15.0%, while the S&P 500 fell 0.1%.
−15.0%, the year's worst day · S&P 500 −0.1%
Where it ended: a close of $0.38 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.07).
Nothing in the past 12 months.
All ONCY dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ONCY and SPY from Benzinga historical bars. Not investment advice.
